Ifosfamide pdf
71. Ginsberg SJ, Comis RL, Miller M 1982 The development of hyponatremia following combination chemotherapy for metastatic germ cell tumors. Med Pediatr Oncol 10: 714 72. Jojart I, Laczi F, Laszlo FA, Boda K, Csati S, Janaky T 1987 Hyponatremia and increased secretion of vasopressin induced by vincristine administration in rat. Exp Clin Endocrinol 90: 213220 73. Abe T, Takaue Y, Okamoto Y, Yamaue T, Nakagawa R, Makimoto A, Sato J, Kawano Y, Kuroda Y 1995 Syndrome of inappropriate antidiuretic hormone secretion SIADH ; in children undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Pediatr Hematol Oncol 12: 363369 74. Meresse V, Vassal G, Michon J, De Cervens C, Courbon B, Rubie H, Perel Y, Landman J, Chastagnier P, De Valck C, Hartmann O 1993 Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 11: 630 637 Mitchell D, Parker LF, Woods SC 1974 Cyclophosphamide-induced sodium appetite and hyponatremia in the rat. Pharmacol Biochem Behav 2: 627 630 Bjorck E, Samuelsson J 1996 Syndrome of inappropriate secretion of antidiuretic hormone SIADH ; after treatment with cyclophosphamide, alpha-interferon and betamethasone in a patient with multiple myeloma. Eur J Haematol 56: 323325 77. DeFronzo RA, Braine H, Colvin M, Davis PJ 1973 Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation. Ann Intern Med 78: 861 869 Steele TH, Serpick AA, Block JB 1973 Antidiuretic response to cyclophosphamide in man. J Pharmacol Exp Ther 185: 245253 79. Bode U, Seif SM, Levine AS 1980 Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med Pediatr Oncol 8: 295303 80. Orbo A, Simonsen E 1992 Cisplatin-induced sodium and magnesium wastage. Eur J Cancer 28A: 1294 81. Vassal G, Rubie H, Kalifa C, Hartmann O, Lemerle J 1987 Hyponatremia and renal sodium wasting in patients receiving cisplatinum. Pediatr Hematol Oncol 4: 337344 82. Lammers PJ, White L, Ettinger LJ 1984 Cis-platinum-induced renal sodium wasting. Med Pediatr Oncol 12: 343346 83. Kurtzberg J, Dennis VW, Kinney TR 1984 Cisplatinum-induced renal salt wasting. Med Pediatr Oncol 12: 150 154 Bjornson DC, Stephenson SR 1983 Cisplatin-induced massive renal tubular failure with wastage of serum electrolytes. Clin Pharm 2: 80 83 Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA 1988 Renal salt wasting in patients treated with cisplatin. Ann Intern Med 108: 2125 86. Ritch PS 1988 Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone. Cancer 61: 448 450 Porter AT 1985 Syndrome of inappropriate antidiuretic hormone secretion during cis-dichlorodiammineplatinum therapy in a patient with an ovarian carcinoma. Gynecol Oncol 21: 103105 88. Littlewood TJ, Smith AP 1984 Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin. Thorax 39: 636 637 Levin L, Sealy R, Barron J 1982 Syndrome of inappropriate antidiuretic hormone secretion following dis-dichlorodiammineplatinum II in a patient with malignant thymoma. Cancer 50: 2279 2282 Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J 1986 Cisplatin nephrotoxicity. J Kidney Dis 8: 356 367 Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C 1981 Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. J Physiol 241: F175 85 92. Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, Rohrbaugh TM, Meadows AT 1985 Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. Cancer 55: 44 46 Rossi R, Ehrich JH 1993 Partial and complete de Toni-DebreFanconi syndrome after ifosfamide chemotherapy of childhood malignancy. Eur J Clin Pharmacol 44[Suppl 1]: S435 94. Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC.
Ifosfamide vp16
This compound in whole blood was associated with these conceivable that a substantial amount of isophosphorcells, 13% was protein bound and 5% was present in amide mustard is transferred from the liver to its site of plasma water; considering the whole blood AUC for action associated with the red blood cell and in effect isophosphoramide mustard, calculated from the haema- never enters the plasma, a situation similar to the transtocrit, 77% was found to reside within the erythrocyte. port of oxygen. It would be instructive to know whether In addition to this high uptake by erythrocytes, the rate an infusion of isophosphoramide mustard itself results of loss from these cells is faster than from plasma in the same distribution pattern in whole blood, as the Figure 1 ; . As the concentration of isophosphoramide liver will no longer be a source of isophosphoramide mustard in the erythrocyte fraction declines, there is no mustard. corresponding increase in chloroethylamine levels, indiIn early models of the interaction between blood and cating that the decline is not due to degradation. We tissues, compounds have been described as entering have also found in vitro data not shown ; , that there is a tissues from the plasma water phase. However other loose association of isophosphoramide mustard with the models propose that inhibition of protein binding occurs erythrocyte, and that this metabolite is released easily on the capillary endothelium releasing protein bound into blank plasma. Therefore erythrocyte mediated compounds to the tissues [12]; as a result tissue levels transport of isophosphoramide mustard within the cir- correspond more closely to the protein bound fraction culation is significant, and transfer to tissues plausible. than to the free fraction. This concept is equally imporFollowing intravenous infusion, most of the ifosfamide tant with regard to erythrocytes, as tissues on the other is carried by erythrocytes and delivered to the liver. It is side of a capillary membrane may be more exposed.
The only significant difference was in the distribution of patients among the chemotherapy regimens chosen at the centres involved, with a higher percentage of the patients in the costing study receiving the cisplatin and vindesine cv ; and mitomycin, ifosfamide and cisplatin mic ; regimens and fewer receiving the mitomycin, vinblastine and cisplatin mvp ; and vinorelbine and cisplatin np ; regimens
Materials and Methods Reagents. WR-1065 mol. wt., 207.16 ; was obtained from U.S. Bioscience Corporation West Conshohocken, PA mesna mol. wt., 164.18; 100 mg ml solution ; from Bristol-Myers Squibb Co. Stamford, CT 4-hydroperoxycyclophosphamide 4-OOH-CP, D-18864; mol. wt., 293.1 ; was obtained from Dr. Ulf Niemeyer ASTA Medica AG, Frankfurt Main, Germany monobromobimane mBBr ; from Molecular Probes Eugene, OR 5, -dithio-bis 2nitrobenzoic acid ; , cysteine Cys-SH ; , GSH, GSSG containing 0.2% GSH ; , Tris, and HPLC grades methanol, acetonitrile AcCN ; , dimethyl sulfoxide DMSO ; , and dichloromethane from Sigma St. Louis, MO trifluoroacetic acid and methanesulfonic acid MSA ; from Fluka Chemical Corp. Ronkonkoma, NY highest purity DTT from Calbiochem San Diego, CA perchloric acid from Aldrich Milwaukee, WI Ficoll-Paque from Amersham Pharmacia Biotech AB Uppsala, Sweden Hanks' balanced salt solution from Invitrogen Carlsbad, CA RPMI 1640 medium pH 7.15, without L-glutamine ; from Mediatech, Inc. Herndon, VA phosphate-buffered saline PBS without calcium or magnesium ; from Bio Whittaker Walkersville, MD and CD45 MicroBeads, OctoMACS magnet, and MiniMACS high-gradient magnetic separation columns with maximum capacity of 108 cells from Miltenyi Biotec Auburn, CA ; . The thiol-bimane derivative, mixed thiol standard, sodium methanesulfonate, mBBr, DTT, and 5, -dithio-bis 2-nitrobenzoic acid ; solutions were prepared and stored as described Souid et al., 1998, 1999 ; . Thiol concentrations were measured by Ellman's reagent Jocelyn, 1987 ; . The detection sensitivity was at the picomole level. A mixed thiol standard solution 2 M each ; was used to generate a calibration curve with each analytical run, which was linear from 5 to 120 pmol r 0.98 ; . Patients. Patient 1 was an 18-year-old male; patient 2, an 18-year-old male; patient 3, a 9-year-old male; patient 4, a 15-year-old male; patient 5, a 19-year-old female; and patient 6, a 7-year-old female. The study was approved by the Institutional Review Board for the Protection of Human Subjects at each of the participating institutions. Informed consent was obtained from each patient. Drug Administration and Pharmacokinetic Sampling. The chemotherapy and pharmacokinetic sampling for patients 1 to 4 were as previously described Souid et al., 1999 ; . Briefly, they received amifostine 825 mg m2 3.1 mmol m2 ; i.v. over 15 min, beginning 30 min before ifosfamide mol. wt., 261.1 ; and cyclophosphamide mol. wt., 279.1 ; infusions. Amifostine was repeated 3 h after the first dose. Mesna 400 mg m2 2.4 mmol m2 dose i.v. ; was given as well, with the first dose just after the first amifostine dose. The cyclophosphamide course started 3 weeks after the ifosfamide course. Patient 5 received mesna 750 mg m2 4.6 mmol m2 dose i.v. ; immediately before a 3-h infusion of 3.0 g m2 11.5 mmol m2 ; of ifosfamide mol. wt., 261.1 ; . Blood samples were collected before mesna infusion, immediately after mesna infusion, and immediately after ifosfamide infusion. Patient 6 received mesna with cyclophosphamide, as follows: 0 to 0.5 h: cyclophosphamide, 1.2 g m2 4.3 mmol m2 ; mesna, 360 mg m2 2.2 mmol m2 ; i.v. over 30 min; 0.5 to 3.5 h: mesna, 360 mg m2 i.v. over 3 h; 3.5.
Doxorubicin and ifosfamide
Rooting depth was 2535 cm and the groundwater level being at 3050 cm depth. The soil profile of each of the stands was analysed, and the soil type was recorded Table 1 ; . Soil was sampled 35 samples per stand ; from ground level to below the former ploughing depth 2030 cm ; . The average texture for 030 cm depth was determined. Soil type was classified in the field in accordance with the instructions provided by Atterberg Ekstrm 1926 ; , and the soils were classified as sediments, tills or organogenic types. Johansson 1999 ; presents detailed information about the technique for soil classification used for this type of object. Site index H40 ; was estimated for each stand using the measured height of the felled trees. Site index was calculated from site index curves for Norway spruces growing on abandoned farmland Johansson 1996a ; , Table 1. A modified "mean tree technique" method was used for biomass estimation. The five largest spruces in the stand determined on the basis of diameter at breast height ; were chosen for sampling. Then one of the tallest trees was chosen for biomass estimation. This technique makes it possible to use the site index estimate based on the top height tree, c.f. Johansson 1996b ; . On ten 100 m2 circular subsample plots in a scatter of the stand, the number of trees and their diameter at breast height were registered Table 1 ; . The basal area weighted mean diameter was calculated for each of the ten sample plots. The means were almost equal and diameters from all measured trees in the stand were used to calculate the basal area weighted mean diameter for the stand. Among the five largest spruces one tree was used as a sample tree if it had an undamaged, straight stem without double leaders, was free from root rot Heterobasidion annosum Fr. ; Bref. ; and was not growing in a large opening. After this tree had been felled, its height m ; , diameter at breast height dbh, mm ; and bark thickness mm ; were measured Table 2 ; . Increment cores were taken at intervals corresponding to 1, 10, 20, and 90 % of tree height. All cores extended to the pith. Total age was recorded Table 2 ; . All branches including the needles on the tree were then cut and weighed fresh in the field, and the fresh weight of the.
Data analysis the daqlab software not only provides real time data readings, but there are extensive features allowing for alternative methods of data display and analysis and iloprost.
Ifosfamide ingredients
Table 3. Unit dose intensities of single agents in first-line therapy for metastatic breast cancer as described by Hryniuk et al. [13] Agent Carboplatin Cyclophosphamide Docetaxel Doxorubicin Epirubicin Etoposide 5-Fluorouracil i.v. bolus Ifosfamide Methotrexate Paclitaxel Thiotepa.
Coma of the urinary bladder. The tumor Stage III ; was large and could only be incompletely surgically resected. Chemotherapy was started with the inner group rhabdomyosarcoma study IV regimen 47 ; . This consisted of vincristine, ifosfamide VP-l6, adriamycin, cytoxan and actinomycin D. The patient never received radiation treatment. This multiple drug regimen was planned for 56 wk of treatment. The patient only received the prescribed doses for 38 wk because of multiple complications related to the chemotherapy. The gastrointestinal problems included persistent nausea and vomiting with anorexia and poor oral intake. This necessitated hyperalimentation. Biopsy proof of gastritis and duodenitis and esophagitis was documented, but, after the biopsy, a traumatic FIGURE2. DMSAimage at 4 hr. duodenal hematoma further complicated the feeding problems. Dilatedcollectingsystemswith mm Over the next 20 mo, recurrent multimicrobial urinary tract imal uptake in the renal paren chyma. infections were documented, including candida cystitis. Because of citrobacter urinary tract infections, a oe Tc-dimercaptosuccinic acid DMSA ; scan was performed at 2.5 yr. An initial scan Fig. 1 ; obtained at 1 hr demonstrated an abnormal pattern ofuptake by the in an animal model to be both sensitive and specific for the diagnosis of acute pyeloneph.ritis 2 ; . In this regard, it is has kidney more reminiscent of an agent undergoing glomerular been shown to be far superior to other imaging modalities, filtration rather than a renal cortical image. A Fanconi-like syn drome of renal tubular damage had been documented earlier including ultrasound examination 3 and indinavir.
Ifosfamide trade name
EYE DROPS OINTMENT S.R.F.C. TABLET COATED TABLETS TABLET TABLET FILM COATED TABLETS OINTMENT PASTE FOR TOPICAL APPLIC. TABLETS NASAL SPRAY SOLUTION GASTRORESISTANT TABLET GASTRORESISTANT TABLET SOLUTION FOR INJECTION TABLETS SOLUTION FOR BUCCAL USE LOZENGE THROAT.
| Ifosfamide doxorubicinNeed to focus attention on the most promising technologies. The report recommended that WHO `should develop the capacity to evaluate advances in genomics, to anticipate their potential for research and clinical application . and to assess their effectiveness and cost in comparison to current practice' World Health Organization, 2002 ; . An essential first step in addressing this recommendation is a technology foresight exercise to identify priority technologies. We have now completed a foresight study that identifies the ten most promising biotechnologies for improving health in developing countries in the next five to ten years. It is the first study to provide such information and infliximab.
Neonates were deeply anesthetized with isoflurane and euthanized by cervical dislocation. Hearts were removed and placed in prewarmed ADS buffer. Each heart was washed free of blood, and the atria and ventricles were dissected into 2- to 3-mm pieces. Buffer was removed by brief centrifugation, and fresh buffer with collagenase type II 0.5 mg mL ; and pancreatin 1 mg mL ; was then added. Digestion was performed at 37C for 15 minutes, after which tubes were quick spun and the supernatant was transferred to DMEM supplemented with 10% horse serum and 5% FBS and placed in a 5% CO2 incubator.
These drying conditions are continued until the residual moisture in the lyophilizate is reduced to a levelwhereby ifosfamide is chemically stable and intal.
|
Patterns of resistance and cross-resistance. Resistant variants of other estrogen-responsive cell lines also have been reported. Although not a full listing, Table 4 describes several antiestrogen-resistant models. This section will focus primarily on those models of apparent pharmacological resistance i.e., cells that do not exhibit a growth response to specific antiestrogens ; . Models that are growth stimulated by TAM are discussed in Section V. The models presented are selected to reflect the most widely used models and the diversity of phenotypes. A. R27 and LY2 These were among the first stable antiestrogen-resistant variants reported. R27 cells were obtained following anchorage-independent cloning of MCF-7 cells in the presence of TAM. The cells retain an attenuated response to estradiol and are resistant to the growth inhibitory activities of TAM Nawata et al., 1981 ; . The LY2 cells were generated by a stepwise selection against the benzothiophene antiestrogen LY 117, 018 Bronzert et al., 1985 ; . While retaining some responsiveness to estrogens, LY2 cells are cross-resistant to 4-hydroxyTAM Bronzert et al., 1985; Clarke et al., 1989c ; and ICI 164, 384 Clarke et al., 1989c ; . Unfortunately, LY2 cells are nontumorigenic, restricting their use to in vitro studies Clarke et al., 1989c ; . The tumorigenicity of R27 cells is not reported. B. MCF-7RR The MCF-7RR subline was obtained by selecting MCF-7 cells for their ability to grow in medium supplemented with 2% calf serum and 1 M TAM Butler et al., 1986 ; . The cells exhibit an altered chromatin structure and chromatin acceptor sites for the antiestrogen 4- N, N-diethylaminoethoxy ; -4 methoxy- ; - p-hydroxyphenyl ; -ethylstilbene Singh et al., 1986 ; . Of interest is MCF-7RR cells' retinoic acid cross-resistance Butler and Fontana, 1992 ; , which has not been fully studied in many other antiestrogen-resistant variants. Whereas the cross-resistance pattern among other antiestrogens is not reported for MCF-7RR, these cells provide a novel model for studying the relationships among responsive.
Ifosfamide side effects
Reduces urinary symptoms and frequency of dysuria, as well as the incidences of macrohematuria and microhematuria, regardless of tumor site when administered, intravenously or orally, concurrently with any dosage of oxazaphosphorine antineoplastic alkylating agents [1] such as ifosfamide [2], cyclophosphamide [3] or trophosphamide. It has also been used as a chemoprotective drug to reduce the nephrotoxicity of carboplatin when administered in combination therapy [4]. MESNA is used also as a mucolytic agent alone or in combinations with mucolytic therapy or with anti-inflammatory drugs [5] and invirase.
21. Bezwoda WR, Seymour L and Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489. Peters WP, Berry D, Vredenburgh JJ, et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard dose CAF for primary breast cancer involving ten or more axillary lymph nodes Due CLGB 8782 ; . Proc Assoc Clin Oncol 1995, A: 933. 23. Gianni AM, Siena S, Bregni M, et al. Five-year results of high-dose sequential adjuvant chemotherapy in breast cancer with ten or more axillary lymph nodes. Proc Assoc Clin Oncol 1995, A: 61 24. McGuire WP, Hoskins WJ, Brady MF, et al. An assessment of dose intense therapy in suboptimally debulked ovarian cancer: a Gynaecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-1599. Ayash LJ, Elias A, Schwartz G, et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of highdose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14: 2984-2992. Socinsky MA, Cannistra SA, Elias A, et al. Granulocyte macrophage colony-stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1986; 1: 1194-1198. Dhrsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 71: 2074-2081. Brugger W, Bross K, Frisch J, et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 1992; 79: 1193-2000. Huhn RD, Yurkow EJ, Tushinski R, et al. Recombinant human interleukin-3 rhIL-3 ; enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor rhG-CSF ; in normal volunteers. Exp Haematol 1995; 24: 839-847. Pettengell R, Luft Th, de Wynter E, et al. Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation. Br J Haematol 1995; 89: 237-242. Basser R, Rasko J, Clarke K, et al. Pegylated megakaryocyte growth and development factor enhances the mobilization of peripheral blood progenitor cells by chemotherapy and filgrastim. Blood 1996; 88 suppl 1: #2554. 32. Brugger W, Hiemfield S, Berenson RJ, et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex-vivo. N Eng J Med 1995; 333: 283-287. Nagler A, Eldor A, Naparstek M, et al. Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro. Exp Haematol 1995; 23: 1268-1274. Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral blood stemcell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670. Cortelazzo S, Viero P, Bellavita P, et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 935-941.
Ifosfamide mechanism
Carol J. Ellick is founding director of the public programs division at Statistical Research, Inc., in Tucson, Arizona. She is also a program manager of the SRI Foundation, advancing historic preservation through education, training, and research and iressa.
Ifosfamide ifosfamide casrn: 3778-73-2 site hazardous decomposition: when heated to decomposition it emits very toxic fumes of hydrogen chloride, nitrogen oxides, & phosphorus oxides and ifosfamide.
Search dictionary mobile register free login phase ii trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer and irinotecan.
Abbreviations. WHO - world health organisation. Entry - evaluation prior to initiation of salvage treatment: TIP - taxol ifosfamide cisplatin. HDCT - high-dose chemotherapy, CET - carboplatin etoposide thiotepa; wks - weeks after autologous stem cell rescue; WBC - white blood cells; PUT - platelets; Hb, hemoglobin, group A - patients with amifostine; group B - patients without amifostine " All differences were not statistically significant with P 0.05 Fisher's exact test ; . b Including two patients with early death immediatly after HDCT. c Including three patients who required hemodialysis. d Without two patients who refused.
Relapse differed for the two groups. Seventy percent of the patients with a low tumor burden received a CHVP or CHOP ACVBP regimen at relapse Table 1 ; . For those patients with a high tumor burden at diagnosis and who had received first-line CHVP, other chemotherapeutic regimens were prescribed at relapse with a combination of etoposide + ifosfamide + mitoxantrone or cisplatine, cisplatine + high-dose cytarabine DHAP, ESAP ; . Availability of new drugs, especially purine analogues. Stage and tumor burden at relapse, 9% of relapsing FL patients received local radiotherapy for stage I--II disease at relapse. Single alkylating agent was mostly given to patients with a low tumor burden at relapse and isdn.
Fig. 6. Freeze-fracture micrographs of T. cruzi wild-type AD ; and gp72 null mutant EF ; epimastigotes. An IMP linear clustering was observed in the Xagellum arrows in A and B ; on both PF and EF faces arrowheads in C and D ; . The cytostome was clearly visible C ; . No specializations were observed in T. cruzi gp72 null mutants E and F the Xagellar necklace was not altered arrow in E and F ; . Xagellum f cell body c cytostome cy ; . Bars: AC and E and F, 1 m; D, 0.1 m and iloprost.
Rituximab ifosfamide carboplatin and etoposide
Anesthetic reversal, radius 7 brooks, proteins rda, heart disease exercise and abate zanella. Membrane dryer, esophagus lesions, pacifier holder tutorial and rupture fightwear or cardiology ep.
Ifosfamide structure
Ifosvamide, ifofsamide, ofosfamide, ifosfamid3, ivosfamide, ifosamide, ifosfamde, ifossfamide, ifosfanide, ifosfmide, ifosfamie, ifsofamide, ifosfamdie, ifosfam8de, ifosfamixe, ifowfamide, ifoosfamide, ifosfamice, ifosfaimde, irosfamide.
Ifosfamide canada
Ifosfamide vp16, doxorubicin and ifosfamide, ifosfamide ingredients, ifosfamide trade name and ifosfamide doxorubicin. Ifosfamide side effects, ifosfamide mechanism, rituximab ifosfamide carboplatin and etoposide and ifosfamide structure or ifosfamide canada.
|
